News Novartis' new SMA gene therapy cleared in EU Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.
News Novartis gets win for another Avidity muscular dystrophy AOC Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.
News Oral Wegovy backed by CHMP at May meeting The CHMP recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral weight loss therapy.
News Novartis reveals more data behind Pluvicto expansion bid Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
News Novartis shares fall as Entresto sales weaken Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.
News New data build case for Roche's oral BTK drug for MS Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.